Genotype and allele frequency of CYP2C19*17 in a healthy Iranian population by Payan, M. et al.
Original Article
http://mjiri.iums.ac.ir Medical Journal of the Islamic Republic of Iran (MJIRI)
Iran University of Medical Sciences
____________________________________________________________________________________________________________________
1. PhD candidate, Biopharmaceutics and Pharmacokinetics Division, Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of
Medical sciences, Tehran, Iran. payan@razi.tums.ac.ir
2. (Corresponding author) Professor of Immunology, Immunology Research Center (IRC), Iran University of Medical Sciences, Tehran, Iran.
nadertajik@yahoo.com, tajik.n@iums.ac.ir
3. Professor, Biopharmaceutics and Pharmacokinetics Division, Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of Med-
ical sciences, Tehran, Iran. rouini@tums.ac.ir
4. Professor, Department of Pharmacology and Toxicology, Faculty of Pharmacy, Tehran University of Medical sciences, Tehran, Iran.
mhghahremani@razi.tums.ac.ir
Genotype and allele frequency of CYP2C19*17 in a healthy
Iranian population
Maryam Payan1, Nader Tajik*2, Mohammad Reza Rouini3
Mohammad Hossein Ghahremani4
Received: 7 Febreuary 2015 Accepted: 8 April 2015 Published: 3 October 2015
Abstract
Background: Cytochrome P450 2C19 (CYP2C19) is important in metabolism of wide range of
drugs. CYP2C19*17 is a novel variant allele which increases gene transcription and therefore results
in ultra-rapid metabolizer phenotype (URM). Distribution of this variant allele has not been well
studied worldwide. The aim of present study was to investigate allele and genotype frequencies of
CYP2C19*17 in a healthy Iranian population and compare them with other ethnic groups.
Methods: One hundred eighty healthy unrelated Iranian volunteer took part in this study and were
genotyped for CYP2C19 *2, *3, *17 (-3402) by using polymerase chain reaction-restriction fragment
length polymorphism (PCR-RFLP) and CYP2C19*17 (-806) by a nested-PCR assays. The distribu-
tion of CYP2C19*17 polymorphism in Iranian population was then compared with other ethnic
groups.
Results: The CYP2C19*17 allele frequency was 21.6% in Iranian population. Among studied sub-
jects 5.5% were homozygous for CYP2C19*17 and phenotyped as ultra-rapid metabolizers; 28.8%
were genotyped as CYP2C19*1*17 (extensive metabolizers) and 3.3% as CYP2C19*2*17 (interme-
diate metabolizers).
Conclusion: The CYP2C19*17 genetic distribution in Iranian population is similar to Middle East
or European countries. The high frequency of CYP2C19*17 in Iranian population highlights the im-
portance of this new variant allele in metabolism of CYP2C19 substrates. Thus, future association
studies are required to reveal clinical consequence of this genetic polymorphism in carrier individu-
als.
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Introduction
The cytochrome P450 2C19 (CYP2C19)
is important in metabolism of a wide range
of drugs including proton pump inhibitors
(omeprazole), tricyclic antidepressants (am-
itriptyline), selective serotonin reuptake
inhibitors (citalopram), anticonvulsant S-
mephenytoin and anti-platet drugs
(clopidogrel) (1-3).
Genetic polymorphism of CYP2C19 was
identified by its considerable effect in me-
tabolism of S-mephenytoin, resulting in
poor metabolizer (PM) and extensive me-
tabolizer (EM) (4). The EM phenotype is
attributed to wide type allele (CYP2C19*1).
The PM is assigned to CYP2C19*2 which
is defined as a mutation in exon 5
(CYP2C19, 681G>A) and causes a splice
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site and CYP2C19*3 (CYP2C19, 636G>A)
which creates a stop codon in exon 4 (5). In
2006 a novel variant allele, CYP2C19*17
was reported by Sim et al. (6) which is
specified by a double mutation in promoter
region (CYP2C19 -806C>T and -
3402C>T) (2), these mutations lead to in-
creased gene transcription and therefore
ultra-rapid metabolizer phenotype (URM)
(7-9).
Few studies have reported allelic frequen-
cy of CYP2C19*17 and its effect on clini-
cal response to CYP2C19 substrates (8,10-
13). CYP2C19*17*17 genotype has been
found to increase clinical response to
clopidogrel treatment by better anti-platelet
activity and therefore was associated with
higher risk of bleeding (14); In treatment of
peptic ulcer, URM phenotype, caused ther-
apeutic failure by increasing proton pump
inhibitor metabolism (15) and PM pheno-
type led to greater acid suppression (16,17).
Several studies show inter-ethnic differ-
ences in distribution of this variant allele
(1,6,17). The allele frequency of
CYP2C19*17 was estimated 18% in Swe-
dish, 4% in Chinese (6) and 1.7% in Japa-
nese people (1). To our best knowledge, no
study has been conducted to evaluate dis-
tribution of this new variant allele in Irani-
an population. Thus, the present study aims
to investigate allele and genotype frequen-
cies of CYP2C19*17 variant in the Iranian
population and compare these frequencies
with other ethnic groups. These findings
would help us to estimate importance of
this new polymorphism in variable re-
sponse to CYP2C19 substrates between
Iranian individuals.
Methods
Subjects and DNA extraction
One hundred and eighty unrelated healthy
Iranian volunteers (60 women and 120
men) with the mean age of 36 years (rang-
ing between 20 and 55) and average body
weight of 63 kg (ranging between 45 and
89) took part in this study. A randomize
prospective cross sectional design was used
to recruit participants. All subjects were
students or stuffs of faculty of pharmacy
from four different cities in Iran. They
signed written informed consent before at-
tending this project. The study protocol was
confirmed by ethics committee of Tehran
University of Medical Sciences.
Five ml venous blood sample was taken
from each subject and transferred into tubes
containing 10 µl of 10% ethylene diamine
tetra-acetic acid (EDTA). Genomic DNA
was obtained from peripheral blood leuco-
cytes by salting out method (using super-
saturated 6M NaCl solution) (18). The ex-
tracted DNA was dissolved in sterile dis-
tilled water and stored at 4 ͦ C until the day
of analysis.
Genotyping of CYP2C19*2 (681G>A),
CYP2C19*3 (636G>A) and CYP2C19*17
(-3402C>T)
The genotyping of CYP2C19*2
(681G>A), CYP2C19*3 (636G>A), and
CYP2C19*17 (-3402C>T) polymorphisms
was performed by modified PCR-RFLP
assays as originally described by De Morais
et al. (19) and Sim et al. (6). The PCR reac-
tion mixture (25 µl) was consisted of 250
ng template DNA, 1× PCR buffer, 2 mM
MgCl2, 0.2-0.8 µM of each specific for-
ward and reverse primers, 0.2 mM dNTPs,
1 Unit of Taq DNA polymerase (CinnaGen,
Iran) and sterile distilled water. The PCR
reaction was carried out in an Eppendorf
PCR system gradient master cycler (Ham-
burg, Germany). Thermal profile for DNA
amplification was as follows: the initial de-
naturation at 94 ͦ C for 2 min; then 35 cy-
cles of denaturation at 94 ͦ C for 45 seconds,
annealing at 53 ͦ C for 40 seconds, and ex-
tension at 72 ͦ C for 30 seconds; final exten-
sion at 72 ͦ C for 5 min eventually applied
to cycling. All three PCR reactions were
amplified by similar thermal profile. The
PCR product of each reaction was digested
by specific restriction endonuclease (New
England Biolabb, UK). The details of pri-
mers sequence and restriction enzymes are
summarized in Table 1. SmaI digested the
169 bp fragment to 120 and 49 bp frag-
ments in wild type (wt) carriers of
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CYP2C19*1.  BamHI yielded 233 and 96
bp fragments in wild type carriers of
CYP2C19*1. MnlI resulted in 280 and 224
bp fragments in wt subjects for
CYP2C19*1. While the homozygous carri-
ers of CYP2C19*2, *3 and *17 were re-
sistant to digestion by related enzymes and
resulted in single band in the 2.5% agarose
gel stained with ethidium bromide (Table
1).
Genotyping of CYP2C19*17 (-806C>T)
The CYP2C19*17 -806C>T mutation was
analyzed by semi-nested PCR approach as
described by Sim et al. with a few modifi-
cations (6). The first PCR reaction mixture
and thermal protocol (PCR I) was identical
to what described earlier for
CYP2C19*2,*3 and *17(-3402); R1 and F1primers (Table 1) yielded a 470 bp product.
0.5 µl of PCR I product was then included
in second allele-specific PCR reactions
(PCR II). Primer F2 (wt) or primer F3 (mt)were used with primer R1 to differentiatebetween -806C (CYP2C19*1) and -806T
(CYP2C19*17) alleles, respectively. The
reaction mixture (15 µl) of PCR II (one re-
action for each allele) was similar to that of
first reaction, except for using 2.5 mM
MgCl2. The second reaction (PCR II) was
performed with initial denaturation at 94 ͦ C
for 1 min, and then 15 cycles at 94 ͦ C for
15 seconds, annealing at 53 ͦ C for 20 se-
conds and extension at 72 ͦ C for 30 se-
conds. The 200 bp PCR products (wt or mt)
were separated by 2.5% agarose gel.
Statistical analysis
The allele frequency differences between
populations were estimated using Chi-squar
test and two tailed Fisher’s exact test. The
95% confidence intervals (CIs) were calcu-
lated using Confidence Interval Analysis
software. The relation of sex and genotype
was analyzed by two tailed Fisher’s exact
test. The observed and expected frequen-
cies were calculated using Hardy-Weinberg
equation. The two tailed Fisher’s exact test
was used to assess genotype frequencies
deviation in the studied population from
Hardy-Weinberg equilibrium. In all statisti-
cal analysis p<0.05 was considered as sig-
nificant difference.
Results
The CYP2C19*17 allele was identified in
78 out of 180 volunteer with the frequency
of 21.6% (95% CI: 17.5 – 26.3). 10 sub-
jects were homozygous for CYP2C19*17
(5.5%, 95% CI: 2.7-10 %), 52 subjects
(28.8%, 95% CI: 22.4-36.1 %) were heter-
ozygous for CYP2C19*17 and 75 subjects
(41.7%, 95% CI: 34.4-49.2%) were found
to be homozygous for CYP2C19*1. The
genotype and allele frequencies of
CYP2C19 are reported in Table 2. The dis-
Table 1. Primer sequences, PCR products, restriction endonucleases, and digested fragments
Gene Primer Sequence PCR prod-
uct (bp)
Restriction endo-
nuclease, T (ºC)
Restriction Pat-
tern (bp)
CYP2C19*2 5'-AATTACAACCAGAGCTTGGC-3' (F) 169 SmaI, 25 Wt:120, 49
5'-TATCACTTTCCATAAAAGCAAG-3' (R) Het:169, 120, 49
Mt: 169
CYP2C19*3 5'-TATTATTATCTGTTAACTAATATGA-3' (F) 329 BamHI, 37 Wt:233, 96
5′ -ACTTCAGGGCTTGGTCAATA-3' (R) Het:329, 233, 96
Mt: 329
CYP2C19*17 5′-AATAAAGATGACCTTGATCTGG-3' (F) 500 MnlI, 37 Wt: 280, 224
(-3402C>T) 5′ -TCTCCTGAAGTGTCTGTAC-3' (R) Het:500,280, 224
Mt: 500
CYP2C19*17 5′ -GCCCTTAGCACCAAATTCTC-3' (F1) 470 _ _(-806C>T)a I 5′ -ATTTAACCCCCTAAAAAAACACG-3' (R1)CYP2C19*17 5′ -TCTGTTCTCAAAGC-3' (F2wt) 200 _ _(-806C>T)b II 5′ -TCTGTTCTCAAAGT-3' (F3mt)
F (Forward primer), R (Reverse primer), bp (Base pair), Wt (wild type), Mt (mutant), Het (heterozygous)
CYP2C19*17(-806C>T) genotyping was performed by semi-nested PCR technique. a R1 + F1 primers were used for first PCR (I) amplification(470 bp). b In second PCR (II), R1 + F2 primers were used for amplification of -806C (wide type) allele and R1 + F3 primers were used for am-plification of -806T (mutant) allele (200 bp).
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tribution of CYP2C19*17 and CYP2C19*2
polymorphisms were not statistically dif-
ferent in the studied men and women
(p>0.05). The expected frequencies of
CYP2C19 genotypes in Iranian population
in this study, had no significant deviation
from the Hardy-Weinberg equilibrium
(p>0.05). Complete linkage disequilibrium
was observed in -806 C>T with that of -
3402C>T and this observation was in ac-
cordance with previously published studies
(1,6,13,20). Both -806 C>T and -3402C>T
mutations were not observed in subjects
homozygous for CYP2C19*2 and accord-
ingly CYP2C19*2 allele was not detected
in subjects homozygous for CYP2C19*17.
CYP2C19*2 allele was present in 43 in-
dividuals (with the frequency of 13.1%;
95% CI: 9.7-16.9 %). Four subjects were
homozygous for CYP2C19*2 (2.2%, 95%
CI: 0.6-5.5%) and 39 subjects were hetero-
zygous for CYP2C19*2 (21.6%, 95% CI:
15.8-28.4%). Six out of these 39 subjects
had both CYP2C19*17 and CYP2C19*2
alleles (3.3%, 95% CI: 1.2-7.1%) and were
genotyped as CYP2C19*2*17, and the rest
of 33 subjects were combination of
CYP2C19*1 and CYP2C19*2 alleles
(18.3%; 95% CI: 13.0-24.7%) and were
genotyped as CYP2C19*1*2. CYP2C19*3
was not identified in our study population.
Based on the CYP2C19 genotypes, sub-
jects were divided into 4 previously defined
phenotypes (2); the summary of predicted
phenotypes is shown in Table 2. Homozy-
gous carriers of CYP2C19*17 allele were
categorized as ultra-rapid metabolizers
(URM). Subjects with CYP2C19*1*17 and
CYP2C19*1*1 genotypes were designated
as extensive metabolizer (EM). Individuals
with CYP2C19*2*17 and CYP2C19*1*2
genotypes were classified as intermediate
metabolizers (IM) and homozygous carrier
of CYP2C19*2 were stratified as poor me-
tabolizers (PM).
The allele and genotype frequencies of
CYP2C19 in this study were also compared
with previously published reports. Data are
summarized in Table 3 and Table 4. Ac-
cording to the data in the Table 3, the allele
frequency of CYP2C19*17 in this study
was not statistically different from Europe-
an and Middle East countries. For example,
the frequency of CYP2C19*17 allele was
20% in Swedish, 20.1 % in Danish, 22% in
Norwegian, 19.6% in Greek, 24.4% in
Turkish and 25.7% in Saudi Arabian people
(6,9,21,23) while in the East and South
Asia like Korea, Thailand and Japan, there
was an statistically significant difference in
allele frequency of CYP2C19*17 with Eu-
ropean and Middle East countries (p< 0.05)
(1,24,25).
Discussion
CYP2C19 is an important factor in the
pharmacokinetic of CYP2C19 substrates
like clopidogrel, imipramine, escitalopram
and proton pump inhibitors (PPIs)
(12,13,15,20, 28). CYP2C19*17 variant
Table 2. CYP2C19 genotype and allele frequencies and expected phenotype in 180 healthy Iranian individuals
CYP2C19
Genotype
Number of subjects Frequency (%) 95% CI Predicted
Phenotype
Expected frequency by
Hardy-Weinberg low a (%)Men (120) Women (60)
*17*17 5 5 5.5 2.7-10.0 URM 4.84
*1*17 37 15 28.8 22.4-36.1 EM 28.6
*1*1 53 22 41.7 34.4-49.2 EM 42.3
*1*2 20 13 18.3 13.0- 24.7 IM 17.0
*2*17 4 2 3.3 1.23-7.1 IM 5.7
*2*2 2 2 2.2 0.6-5.5 PM 1.70
Alleles No. of alleles Frequency (%) 95% Confi-
dence Interval
CYP2C19*17 78 21.6 17.5-26.3
CYP2C19*1 235 65.3 60.1-70.2
CYP2C19*2 47 13.1 9.7-16.9
CYP2C19*3 0 0 0
Abbreviations: UM, Ultra-rapid metabolizer, Het-EM, Heterozygous extensive metabolizer, EM, Extensive metabolizer; IM, Intermediate me-
tabolizer; PM, Poor metabolizer. CI: Confidence Interval
a Observed and expected frequencies were not statistically different (p>0.05).
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that was identified by Sim et al. and report-
ed to be associated with higher metabolic
activity of CYP2C19. This variant allele
has a different genetic distribution in vari-
ous ethnic groups (6). Several studies have
shown the effect of CYP2C19*17 polymor-
phism on treatment of peptic ulcer disease
(10,15,20,30). The data in the different
studies indicate that CYP2C19*17*17 is
associated with 2.1 fold lower omeprazole
plasma concentration and therefore the ef-
ficacy of PPIs like omeprazole is decreased
in CYP2C19*17*17 individuals (10,15,20).
Musumba et al. investigated the effect of
CYP2C19*17 allele on occurrence of peptic
ulcer disease (PUD) and showed increased
prevalence of PUD in patient with
CYP2C19*17*17 genotype in comparison
to CYP2C19*1*1 genotype (30).
CYP2C19*17 allele also leads to lower risk
of breast cancer by increasing estrogen me-
tabolism (31).
The distribution of CYP2C19*17 poly-
morphism has not been well estimated
worldwide. The main goal of present study
was to investigate allele and genotype fre-
quencies of CYP2C19*17 in Iranian popu-
lation. In this study the allele frequency of
CYP2C19*17, *2 and *1 were 21.6%,
13.1% and 65.3% respectively which is in
agreement with previous study in our lab
for CYP2C19*2 and *1 (32). In our previ-
Table 3. Comparison of CYP2C19 allele frequencies between Iranians and different populations
Population Sample size CYP2C19 Allele Frequency (%) Reference
19*17 19*1 19*2 19*3 Others
Iranian 180 21.7 65.3 13.0 0 0 Present study
Japanese 165 1.3 a 57.9 27.9 a 12.8 a 0 1
Swedish 314 18.0 NR NR 0 0 6
Ethiopian 190 18.0 NR NR 0 0 6
Chinese 68 4.0 a NR NR 0 0 6
Danish 276 20.1 64.9 15.0 0 0 9
Faroese 311 15.4 a 65.9 18.7 a 0 0 9
Norwegian 309 22.0 62.8 15.2 0 0 9
Polish 78 28.2 56.4a 15.4 0 0 10
Greek 283 19.61 67.32 13.07 0 0 21
Saudi Arabian 201 25.7 62.9 11.2 0 0 22
Turkish 244 24.4 65.6 10.0 0 0 23
Korean 150 0.3 a 61.0 28.0 a 11.0 a 0 24
Swedish 185 20.0 64.0 16.0 0 0 24
Thai 1051 4.0 a 63.0 27.0 a 6 0 25
Indian 206 17.9 42.0a 40.2 a 0 0 26
Korean 271 1.5 a 60.0 28.4 a 10.1 a 0 27
German 186 25.5 59.3 15.2 0 0 28
Ashkenazi Jewish 342 13.0 70.0 12.0 0 4.1 29
African American 149 19.0 63.0 12.0 0 4.6 29
Hispanic 346 10.0 a 75.0 10.0 0 1.74 29
NR: Not reported
a Represent statistically significant difference in comparison to present data (p<0.05)
Table 4. Comparison of CYP2C19 genotype frequencies between Iranians and different populations
Population Sample Size CYP2C19 genotype frequency (%) Reference
17*17 1*17 1*1 2*17/3*17 1*2/1*3 2*2/2*3/3*3
Iranian 180 5.5 28.9 41.7 3.3 18.3 2.2 Present Study
Japanese 165 0.0 1.1 a 35.5 1.5 43.8 a 18.8 a 1
Danish 276 5.1 22.8 44.2 7.3 18.5 2.2 9
Faroese 311 3.5 16.4 a 46 7.4 23.5 3.2 9
Norwegian 309 4.9 26.5 39.5 7.8 20.1 1.3 9
Greek 283 3.2 28.6 44.17 4.3 17.8 2.1 21
Saudi Arabian 201 7.0 30.4 40.3 7.0 14.5 0.4/0.4 22
Turkish 244 6.6 30.3 44.3 5.3 12.3 1.2 23
Thai 1051 0.0 4.3 a 40.7 0.0 35.1 a/6.85 7.32 a/5.61/0.1 25
Indian 206 1.2 a 20.7 16.1 a 12.6 a/0 31.0 a/0 18.4 a 26
Korean 271 0.0 1.1 a 35.7 1.4 a/0.3 36.5 a/10.7 5.9/7.0/1.1 27
a Represent statistically significant difference in comparison to present data (p<0.05)
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ous study subjects that were genotyped as
CYP2C19*1*17 and CYP2C19*17*17 in
this study were identified as
CYP2C19*1*1; so, if genotype frequencies
of CYP2C19*1*17 and CYP2C19*17*17
(28.8% and 5.5%) is deduced from
CYP2C19*1*1 genotype frequency in pre-
vious report (75%), the similar frequency
for CYP2C19*1*1 (40.55%) is attained.
Accordingly, people with CYP2C19*2*17
in this study were defined as
CYP2C19*1*2 in previous report, so, if we
recalculate the CYP2C19*1*2 genotype
frequency by deduction of the
CYP2C19*2*17 frequency in this study
(3.3%) form CYP2C19*1*2 genotype fre-
quency in the previous study (22%), the
frequency of 18.7% for CYP2C19*1*2 is
obtained which is similar to the result of
this study (18.3%).
Based on the results of this study, there is
not a significant difference in distribution
of CYP2C19*17 variant allele in Iranian
population compared with European and
other Middle East countries. In contrast,
east and south Asian people have signifi-
cantly lower frequency of this polymor-
phism than Iranians.
CYP2C19*2 allele reduces enzyme activi-
ty and CYP2C19*17 allele increases en-
zyme activity (6). In this study, subjects
with CYP2C19*2*17 were categorized as
IM. Few studies have reported effect of
CYP2C19*2*17 on metabolic capacity of
this enzyme (2,13,21,26). In the study by
Gurbel et al. (2) the CYP2C19 activity in
stented patients treated with clopidogrel
was similar in both CYP2C19*2*17 and
CYP2C19*1*2 genotypes. Therefore, it was
concluded that in patients carrying both *2
and *17 alleles the reduction of enzyme
activity by *2 allele is more predominant
than induction of enzyme activity by *17
allele, consequently, in this study
CYP2C19*2*17 genotype was classified as
IM.
Finally, although genotype-based pheno-
type prediction is not the best and complete
way for estimation of protein activity be-
cause other factors like sex, age and associ-
ated disease, combination therapy and envi-
ronmental factors may influence this rela-
tionship, the high frequency of CYP2C19*
17 in Iranian population makes this new
variant allele suitable candidate for associa-
tion studies and help us to reveal clinical
consequences of this genetic polymorphism
in carrier individuals.
Conclusion
The allele frequency of CYP2C19*17 in
Iranian population is 21.6% and is similar
to Middle East or European countries. The
high frequency of CYP2C19*17 allele in
Iranian population highlights the im-
portance of this new variant allele in me-
tabolism of CYP2C19 substrates. Future
association studies are required to reveal
clinical consequence of this genetic poly-
morphism in carrier individuals.
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